NYRA website preview
public medtech Wien, AT 3 sources
Own this company? Claim the page to unlock editing and verified-owner badge.

nyra health GmbH provides innovative, evidence-based neurological therapy solutions to make treatment accessible to everyone, utilized in over 100 clinics.

Classification

Wien AT public medtech saas b2b ai HealthWellnessDigital HealthPersonalized CareData Insights

Profile

Headcount
500-1000

Funding

Funding details not yet available.

Business model
💡 Value Proposition

Accessible, evidence-based neurological therapy solutions that help patients regain daily life through innovative, clinically validated tools.

👥 Customer Segments

Clinical institutions (over 100 clinics) and patients, serving a user base of over 40 million people.

💰 Revenue Model

Free for patients; B2B enterprise model for clinics. Specific pricing structure is not disclosed in the snippets.

📡 Channels

Direct integration into clinical workflows across partner hospitals and clinics.

🤝 Key Partnerships

Over 100 clinical institutions and healthcare partners who trust and utilize their solutions daily.

⚖️ Cost Structure

R&D for evidence-based therapeutic solutions; platform maintenance; clinical partnership management.

🏗️ Key Resources

Proprietary evidence-based therapeutic technology, clinical expertise, and a large user base of 40 million.

⚙️ Key Activities

Developing innovative neurological therapy solutions and maintaining clinical partnerships for daily deployment.

💬 Customer Relationships

B2B2C model relying on clinical trust and integration within hospital systems rather than direct consumer sales.

Strategic analysis
🏁 Competitive landscape

Competes in the neurological rehabilitation sector, differentiating through evidence-based innovation and widespread clinical adoption.

🎯 Market pains

Rising prevalence of neurological diseases (projected 50% increase by 2050) and limited access to effective neurological rehabilitation.

💎 Improvement suggestions
  • Accelerate US Market Entry
🛡️ Credibility notes

The MDR Class IIa certification and multiple RCT publications provide a solid clinical foundation, reducing adoption risk for hospitals and · Series A €20 M funding from reputable venture partners validates market confidence and supplies runway for EU-US expansion

Team
CEO
Investors

No investors recorded yet.

Sources & references

Web verified · 3 sources
Enriched 18 Jun 2026